8 results on '"Choi, Seung Ho"'
Search Results
2. Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer.
- Author
-
Yang, Chan, Roh, Jong-Lyel, Kim, Min-Ju, Lee, Sang-wook, Kim, Sung-Bae, Choi, Seung-Ho, Nam, Soon, Kim, Sang, Yang, Chan Joo, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
HEAD & neck cancer treatment ,QUALITY of life ,HEALTH outcome assessment ,HEAD & neck cancer patients ,MEDICAL statistics ,TREATMENT effectiveness ,FATIGUE (Physiology) ,MENTAL health ,GASTROSTOMY ,HEAD tumors ,LONGITUDINAL method ,MULTIVARIATE analysis ,PROGNOSIS ,NECK tumors ,QUESTIONNAIRES ,SQUAMOUS cell carcinoma ,PROPORTIONAL hazards models ,PSYCHOLOGY ,SURGERY - Abstract
Purpose: Quality of life (QOL) scores in cancer patients are associated with disease course and treatment outcomes. The aim of this study was to prospectively evaluate the associations between pretreatment QOL scores and survival or functional outcomes in patients with head and neck squamous cell carcinoma (HNSCC).Methods: This prospective study enrolled a total of 141 patients with previously untreated HNSCC who underwent curative treatments from October 2010 to March 2012. Patients completed questionnaires on QOL including the European Organization of Research and Treatment of Cancer 30-item Core QOL questionnaire (EORTC QLQ-C30) and EORTC QOL questionnaire Head and Neck Cancer module (QLQ-H&N35). Univariate and multivariate analyses were used to identify QOL scores significantly associated with overall survival (OS), disease-free survival (DFS), and functional outcomes of gastrostomy or tracheostomy dependence.Results: The 2-year OS and DFS rates were 82.3 and 78.0%, respectively. The rates of gastrostomy and tracheostomy dependence were 9.2 and 14.9%, respectively. After controlling for clinical factors, specific QOL indices of 'dyspnea' (hazard ratio 1.023 [95% confidence interval 1.006-1.039]) and 'appetite loss' (1.020 [1.005-1.034]) were significantly associated with OS, while 'insomnia' (1.013 [1.002-1.025]) and 'appetite loss' (1.014 [1.001-1.026]) scores were significantly predictive of DFS (P < 0.05). Global health status score (0.967 [0.935-1.000]) and fatigue (1.048 [1.010-1.086]) were significantly associated with the dependence of tracheostomy (P < 0.05). There was no relationship between gastrostomy dependence and QOL indices.Conclusion: This study provides evidence of significant relationships between certain pretreatment QOL measures and survival or functional outcomes in HNSCC patients. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
3. Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer.
- Author
-
Shin-Ae Kim, Jong-Lyel Roh, Sang-Ah Lee, Sang-wook Lee, Sung-Bae Kim, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim, Kim, Shin-Ae, Roh, Jong-Lyel, Lee, Sang-Ah, Lee, Sang-Wook, Kim, Sung-Bae, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
HEAD & neck cancer ,PATIENT psychology ,MENTAL depression ,NUTRITION ,QUALITY of life ,SURVIVAL analysis (Biometry) ,SERUM albumin ,HEAD tumors ,LONGITUDINAL method ,NECK tumors ,PROGNOSIS ,PSYCHOLOGICAL tests ,QUESTIONNAIRES ,NUTRITIONAL status ,SQUAMOUS cell carcinoma ,PSYCHOLOGY - Abstract
Background: The emotional status of cancer patients is associated with disease course and treatment outcomes. In this study, the authors evaluated associations between the presence of pretreatment depression and pretreatment quality of life (QOL), nutritional status, and survival outcomes in patients with head and neck squamous cell carcinoma (HNSCC).Methods: For this prospective study, 241 patients with previously untreated HNSCC who underwent curative treatments were enrolled. Patients completed the Beck Depression Inventory (BDI)-II, the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core QOL Questionnaire (QLQ-C30), and the EORTC QLQ Head and Neck Cancer module (QLQ-H&N35). EORTC QLQ scores were compared between depressive and nondepressive patients, as determined according to pretreatment BDI-II scores ≥ 14 and <14, respectively. Univariate and multivariate analyses were performed to assess whether the presence of depression was associated with overall survival, disease-free survival (DFS), or posttreatment changes in nutritional status and laboratory data.Results: Pretreatment depression was present in 60 patients (24.9%). In depressive and nondepressive patients, the 3-year overall survival rates were 70.8% and 82.7%, respectively (P = .045), and the 3-year DFS rates were 63.5% and 79.1%, respectively (P = .015). After controlling for clinical factors, the presence of depression was predictive of 3-year DFS (P = .032). EORTC QLQ-C30 and QLQ-HN35 scores on all items except feeding tube, nutritional supplement, and problem with mouth opening differed between depressive and nondepressive patients (P < .05). Depressive patients had lower pretreatment serum albumin levels than nondepressive patients (P < .05).Conclusions: There was a significant correlation between pretreatment depression and pretreatment QOL, nutritional status, and survival outcomes in patients with HNSCC. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Effect of Metformin on Progression of Head and Neck Cancers, Occurrence of Second Primary Cancers, and Cause-Specific Survival.
- Author
-
Kwon, Minsu, Roh, Jong‐Lyel, Song, Jihyun, Lee, Sang‐Wook, Kim, Sung‐Bae, Choi, Seung‐Ho, and Nam, Soon Yuhl
- Subjects
METFORMIN ,SECONDARY primary cancer ,CHI-squared test ,CONFIDENCE intervals ,DIABETES ,FISHER exact test ,HEAD tumors ,NECK tumors ,RESEARCH funding ,STATISTICS ,SURVIVAL analysis (Biometry) ,SURVIVAL ,DATA analysis ,CONTINUING education units ,RETROSPECTIVE studies ,DATA analysis software ,DESCRIPTIVE statistics ,KRUSKAL-Wallis Test ,DISEASE complications ,DIAGNOSIS ,TUMOR risk factors - Abstract
Background. This study aimed to investigate the effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival. Methods. This study analyzed a retrospective cohort of 1,151 consecutive patients with head and neck squamous cell carcinoma who were treated at our hospital. Patients were divided into three groups: nondiabetic, nonmetformin, and metformin. Clinical characteristics, recurrence of index head and neck cancer, occurrence of second primary cancer, and survival were compared among the different groups. Results. Of 1,151 patients, 99 (8.6%) were included in the metformin group, 79 (6.8%) were in the nonmetformin group, and 973 (84.5%) were in the nondiabetic group. Diabetic status and metformin exposure had no significant impact on index head and neck cancer recurrence or second primary cancer development (p > .2). The nonmetformin group showed relatively lower overall (p = .017) and cancer-specific (p = .054) survival rates than the other groups in univariate analyses, but these results were not confirmed in multivariate analyses. Conclusion. Metformin use did not show beneficial effects on index tumor progression, second primary cancer occurrence, and cause-specific survival in patients with head and neck cancer compared with nonmetformin users and nondiabetic patients. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
5. Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.
- Author
-
Park, Marn Joon, Roh, Jong-Lyel, Kim, Sung-Bae, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
CANCER treatment , *SQUAMOUS cell carcinoma , *HEAD tumors , *NECK tumors , *BIOMARKERS , *BLOOD cell count , *BLOOD protein disorders , *C-reactive protein , *LONGITUDINAL method , *MULTIVARIATE analysis , *STATISTICS , *SURVIVAL , *TIME , *TUMOR classification , *COMORBIDITY , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *PROGNOSIS , *TUMOR treatment - Abstract
Background Circulating biomarker (CB) is a convenient, emerging predictive tool for treatment response and outcomes in human cancers. Therefore, we examined the prognostic value of pre-treatment and early post-treatment CBs and their summated scores in patients with head and neck squamous cell carcinoma (HNSCC). Methods This study prospectively included 310 consecutive patients who underwent definitive treatment for previously untreated advanced-stage HNSCC between 2010 and 2015. The CB score was determined by complete blood counts (CBCs) and blood chemistry before and 2 months after the treatment, and the number of abnormal CB was counted from 0 to 10. Univariate and multivariate analyses with Cox proportional hazards models were used to find factors associated with disease-free survival (DFS) and overall survival (OS). Results Most CBC profiles were significantly changed at 2-months post-treatment compared with those at pre-treatment. Univariate analyses showed that hypoalbuminemia, leucocytosis, C-reactive protein, high CB scores (≥6), age, performance status and comorbidity and tumour site were significantly associated with DFS and OS (all P < 0.05). Both pre- and post-treatment CB scores were independent factors predictive of DFS and OS outcomes in the multivariate analyses ( P < 0.05). High CB scores at pre-treatment were associated with 7–10-fold increased risk of unfavourable DFS and OS outcomes, and those at 2-months post-treatment were associated with 2 to 4-fold increased risk of poor survival outcomes (all P < 0.05). Conclusions CB scores at pre-treatment and early post-treatment are useful for predicting survival outcomes in patients with advanced-stage HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. 18F-FDG PET/CT surveillance for the detection of recurrence in patients with head and neck cancer.
- Author
-
Kim, Shin-Ae, Roh, Jong-Lyel, Kim, Jae Seung, Lee, Jeong Hyun, Lee, Sang Hoon, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
CANCER relapse , *EVALUATION of diagnostic imaging , *NECK tumors , *COMBINED modality therapy , *COMPUTED tomography , *HEAD tumors , *PROBABILITY theory , *SQUAMOUS cell carcinoma , *SURVIVAL analysis (Biometry) , *POSITRON emission tomography , *LOGISTIC regression analysis , *DATA analysis , *PROPORTIONAL hazards models , *RECEIVER operating characteristic curves , *SURGERY , *DIAGNOSIS - Abstract
Background Posttreatment detection of recurrence may lead to salvage treatment and prognostic prediction in patients with head and neck squamous cell carcinoma (HNSCC). We evaluated the diagnostic and prognostic values of 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) after definitive treatment of HNSCC. Methods This prospective study included 278 consecutive patients who underwent curative surgery ( n = 143, 51.4%) or definitive radiotherapy/chemoradiotherapy ( n = 135, 48.6%) for previously untreated HNSCC. The patients were regularly followed up and evaluated by 18 F-FDG PET/CT, head and neck CT/magnetic resonance imaging (MRI), and chest CT at regular intervals after treatment. The imaging interpretations were compared with the histological results for recurrence. Receiver operating characteristics curves analysis, McNemar's test and logistic regression using generalised estimating equations were used to compare the diagnostic accuracy of 18 F-FDG PET/CT and standard imaging of CT/MRI or chest CT, and a Cox proportional hazards model was used to assess the prognostic value of PET/CT. Results During a median follow-up of 44 months (range, 24–62 months), 73 patients (26.3%) had recurrence or persistent diseases. The area under curves for 18 F-FDG PET/CT and CT/MRI were 0.975 (0.964–0.992) and 0.789 (0.713–0.874), respectively ( P < 0.001). 18 F-FDG PET/CT detected 65 of 66 recurrences (98.5%) not suggested by physical examination and endoscopy. Positive findings on 18 F-FDG PET/CT scans were independent predictors of poorer cancer-specific and overall survival outcomes ( P < 0.01). Conclusions Posttreatment 18 F-FDG PET/CT surveillance helps to properly detect recurrence and to predict the survival following treatment of HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Impact of 18F-FDG PET/CT staging on management and prognostic stratification in head and neck squamous cell carcinoma: A prospective observational study.
- Author
-
Ryu, In Sun, Roh, Jong-Lyel, Kim, Jae Seung, Lee, Jeong Hyun, Cho, Kyung-Ja, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
DEOXY sugars , *HEAD tumors , *LONGITUDINAL method , *METASTASIS , *NECK tumors , *RADIOPHARMACEUTICALS , *SURVIVAL , *POSITRON emission tomography , *TUMOR classification , *PROGNOSIS - Abstract
Background Accurate assessment of the extent of cancer is essential for appropriate treatment planning and outcome prediction. This study prospectively evaluated whether adding 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) to the routine initial staging practice in head and neck squamous cell carcinoma (HNSCC) improved management and prognosis. Methods All consecutive patients with newly diagnosed HNSCC who presented in October 2010 – December 2012 underwent conventional workups (CWU) followed by PET/CT. The clinical stage and management plans before and after PET/CT were compared. PET/CT was deemed to have no/low, moderate, and high impact on management planning depending on whether PET/CT changed the treatment modality or goal. The appropriateness of PET/CT staging and management impact was confirmed by histopathology and clinical follow-up, and its association with survival was analysed. Findings Of the 248 patients, PET/CT changed the Tumour Node Metastasis (TNM) classification in 79 (31.9%). In the patients with discordant staging, PET/CT staging was significantly more sensitive and accurate than CWU staging (both P < 0.001). PET/CT had high or moderate impact on management in 39 (15.7%) patients. Patients with PET/CT upstaged disease had significantly worse progression-free survival (PFS) and overall survival (OS) than patients with no CWU-stage changes (3-year PFS = 56.8% versus 74.5%, P = 0.043; 3-year OS = 61.3% versus 85.3%, P = 0.006). Multivariate analyses revealed that PET/CT staging and second primary cancer were independent predictive factors for both PFS and OS ( P < 0.05, each). Interpretations 18 F-FDG PET/CT added important staging information that improved management and prognostic stratification in HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Risk factors for survival of head and neck soft tissue sarcomas: A comparison between 7th and 8th edition AJCC staging systems.
- Author
-
Ku, Ja Yoon, Roh, Jong-Lyel, Cho, Kyung-Ja, Song, Joon Seon, Choi, Seung-Ho, Nam, Soon Yuhl, and Kim, Sang Yoon
- Subjects
- *
SARCOMA , *CHEMORADIOTHERAPY , *ISOLATION perfusion , *PROGRESSION-free survival , *HEAD tumors , *RESEARCH , *RESEARCH methodology , *PROGNOSIS , *EVALUATION research , *MEDICAL cooperation , *TUMOR classification , *COMPARATIVE studies , *KAPLAN-Meier estimator , *NECK tumors - Abstract
Objectives: Soft tissue sarcomas of the head and neck (HNSTS) show various histological types and clinical behaviour. Recently, the 8th edition of the American Joint Committee on Cancer (AJCC) proposed a staging system for HNSTS independent of other body soft tissue sarcomas, which requires validation. Therefore, we evaluated the prognostic factors for the survival of HNSTS patients through a comparison between previous and current AJCC staging systems.Materials and Methods: This study involved 135 consecutive HNSTS patients who underwent primary surgery, chemoradiotherapy or chemotherapy. Patients were grouped into staged (S) and not staged (NS) cancer according to the AJCC 8th edition staging. Cox proportional-hazard regression analyses were used to identify factors associated with overall survival (OS), and progression-free survival (PFS) in all, S or NS patients.Results: Median follow-up period was 75 months and the 5-year OS and PFS rates of all patients were 67.8% and 53.4%, respectively, which was similar between S and NS groups. Age, tumour size and grade, overall stage (7th edition) and resection margin were the significant prognostic factors for OS and PFS in all patients and NS group (all P < 0.05), whereas positive resection margin was the only significant factor for OS and PFS in the S group (P < 0.001). While OS was poorly discriminated among different 8th edition T-categories, different 7th edition showed good discrimination among overall stages in all patients and the NS group.Conclusion: The revised staging system may not provide an improved risk stratification for survival of HNSTS patients. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.